Table 4.
Review of the literature of retrospective series about SBRT for oligometastases of breast cancer.
| Author | Primary | Definition | n patients | Follow-up | OS | PFS | LC |
|---|---|---|---|---|---|---|---|
| Fumagalli et al. (12) | Indifferent | ≤5 sites | 90 | 1 year | / | 27% | 84.5% |
| Lung/Liver | |||||||
| (breast=8) | 2 years | 70% | 10% | 66.1% | |||
| Mahadevan et al. (13) | Indifferent | liver | 427 | Median | 22 months | / | / |
| (breast=42) | Breast | 21 months | / | / | |||
| Bhattacharya et al. (14) | Indifferent | ≤3 sites | 76 | 1 year | 84.4% | 49.1% | / |
| (breast=14) | 2 years | 63.2% | 26.2% | / | |||
| Onal et al. (15) | Breast | ≤5 sites | 22 | 1 year | 85% | 38% | 100% 88% |
| Liver | 2 years | 57% | 8% | ||||
| Weykamp et al. (16) | Breast | ≤3 sites | 46 | 2 years | 62% | 17% | 89% |
| Our series | Breast | ≤5 sites | 44 | 1 year | 93% | 81% | 100% |
| 2 years | 87% | 59% | 100% | ||||
| 3 years | 81% | 45% | 100% |
With T, follow-up time; OS, overall survival; PFS, progression-free survival; LC, local control; BM, bone metastasis.With T, follow-up time; OS, overall survival; PFS, progression-free survival; LC, local control; BM, bone metastasis.With T, follow-up time; OS, overall survival; PFS, progression-free survival; LC, local control; BM, bone metastasis.